I know who Prof Bennett is - a very prominent specialist.I just...

I know who Prof Bennett is - a very prominent specialist.

I just watched her segment in the Investor Call. Her presentation seem to portray RAT clinical sensitivity incorrectly, as it is at odds with that which is published on the TGA website?

Earlier RAT kits (ie: Roche kit) had a clinical sensitivity of ~80%, but all since approved since the earlier kits now boast around 95% or more!

It is really the Clinical Specificity that is the issue for RAP anyway.




I just don't know how RAP becomes 'front-of-mind' and starts generating revenue in this segment, when the majority of the time the App is useless (asymptomatic variant / variant that has no cough symptoms like Omicron), very poor clinical specificity so result totally unreliable. Who would be rushing to pay-per-use for that!?